Pfizer
Cecile Guegan has an extensive work experience spanning over several decades. Cecile began their career at AIESEC in 1995, where they served as the VP of Finance until 1996. Following this, they joined PSYGNOSIS as a Business Analyst from 1996 to 1998. In 2005, Cecile joined Pfizer and held various roles, including EMEA Finance Director, VP Finance & CFO Asia Pacific & Nutritionals, VP Finance & CFO EMEA / Canada, VP Finance, Nutrition, VP Finance, Oncology, and VP Finance, R&D and Business Office. Cecile'slatest role at Pfizer is Senior Vice President Finance, Biopharmaceuticals Business, which began in September 2022.
Cecile Guegan attended Brest Business School from 1992 to 1995. Prior to that, they attended Coat, Lanrodec, and Saint Jean Bosco from 1985 to 1988. No degree or field of study information is provided for any of these education experiences.
Pfizer
605 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.